Abstracts tagged "rheumatoid arthritis"

Abstract Number: 123 • 2014 ACR/ARHP Annual Meeting
Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis
Yohei Kirino¹, Maasa Hama¹, Kaoru Minegishi-Takase¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Ryusuke Yoshimi¹, Yukiko Asami¹, Atsushi Ihata², Shigeru Ohno³, Atsuhisa Ueda¹, Mitsuhiro Takeno⁴ and Ishigatsubo Yoshiaki¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ³Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁴Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose , Categorizing RA patients who require intensive treatments is highly warranted to optimize the therapy and to avoid overtreatments. We here evaluated the use…
Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting
Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree¹, Munitta Muthana¹, J. Mark Wilkinson², Anthony G. Wilson¹ and Mohammed Akil³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven¹, Y. Tanaka², R. Riese³, M. Lamba³, T. Kawabata³, T. Hirose⁴, S. Toyoizumi⁴, A. Hazra³ and S. Krishnaswami³, ¹The Karolinska Institute, Stockholm, Sweden, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…
Abstract Number: 2785 • 2014 ACR/ARHP Annual Meeting
Joint Specific Positional Differences in Coding and Noncoding Transcriptome of Synovial Fibroblasts As a Determinant of the Susceptibility of Synovial Joints to Rheumatoid Arthritis
Caroline Ospelt¹, Maria Armaka², Giancarlo Russo³, Anna Bratus³, Michelle Trenkmann⁴, Emmanuel Karouzakis¹, Christoph Kolling⁵, Renate E. Gay⁴, George Kollias⁶, Steffen Gay¹ and Mojca Frank Bertoncelj¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Institute of Immunology,, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece, ³Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁵Schulthess Clinic, Zurich, Switzerland, ⁶Institute of Immunology, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece
Background/Purpose The molecular mechanisms underlying the topographic differences in the susceptibility of synovial joints to develop rheumatoid arthritis (RA) are unknown. Positional embryonic expression of…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Tristan Pascart¹, Rene-Marc Flipo², Xavier Deprez³ and Eric Houvenagel⁴, ¹Rheumatology, Saint-Philibert Hospital, Lille, France, ²Rheumatology, University Hospital Lille, Lille, France, ³Rhumatologie, Ch De Valenciennes, Valenciennes, France, ⁴Rheumatology, Saint-Philibert Hospital, LOMME, France
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret^®)?
Barbara Missler-Karger¹, Hans-Eckhard Langer², Mika Leinonen³ and Björn Pilström⁴, ¹Rheumatology consultant, Cologne, Germany, ²RHIO Research Institute, Düsseldorf, Germany, ³4Pharma AB, Stockholm, Sweden, ⁴TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…
Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting
ALX-0061, an Anti-IL-6R Nanobody^®foruse in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
Maarten Van Roy¹, Ariella Van De Sompel², Kristi De Smet², Jasper Jacobs², Tinneke Denayer² and Hans Ulrichts³, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Stacey Chang¹, Laura Sawyer¹ and Fred Dejonckheere², ¹Symmetron Limited, London, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
Mate Ongenaert¹, Sonia Dupont², Béatrice Vayssière², Reginald Brys¹, Luc Van Rompaey¹, Christel Menet¹ and René Galien², ¹Galapagos NV, Mechelen, Belgium, ²Galapagos SASU, Romainville, France
Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
V. Strand¹, A. Dikranian², J. Beal³, K. Kwok³, S. Krishnaswami⁴, S. Wood⁴ and C. Nduaka⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
Abstract Number: 1463 • 2014 ACR/ARHP Annual Meeting
Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis
Li Zheng¹, Fanlei Hu², Yingni Li¹, Lianjie Shi², Xiaoxu Ma¹, Xuewu Zhang³ and Zhanguo Li⁴, ¹Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ³11 South Street, XiZhiMen , We, Peking University People's Hospital, Beijing, China, ⁴Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose . Dkk-1, a master regulator of joint remodeling, is elevated and leads to bone resorption in patients with RA. This study aimed to investigate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].